Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Emyria Ltd ( (AU:EMD) ) just unveiled an update.
Emyria Limited reported significant clinical outcomes from its PTSD treatment program, with patients showing substantial improvements in symptoms and quality of life. The company also launched a treatment-resistant depression program, engaged with health funders for pilot programs, restructured its leadership, and expanded its treatment capacity by opening a new Empax Centre.
More about Emyria Ltd
Emyria Limited specializes in developing and delivering innovative treatments for mental health and select neurological conditions.
YTD Price Performance: -13.33%
Average Trading Volume: 185,843
Technical Sentiment Signal: Buy
Current Market Cap: A$12.77M
For detailed information about EMD stock, go to TipRanks’ Stock Analysis page.